Glycocalyx-Edited MSC Therapy for Advanced Osteoporosis: First-in-Human Trial Results Published in Cell

The first-in-human trial of glycocalyx-edited autologous MSCs shows that engineering bone homing via sLeX expression reduces fragility fractures and increases bone density in advanced osteoporosis patients, with five-plus years of safety data and no serious adverse events.

Читать далее...

MSC Therapy for Alzheimer’s Disease: Clinical Trial Data on Laromestrocel and Biomarker Outcomes

Recent Phase 2a clinical trials demonstrate that mesenchymal stem cell therapy can slow brain atrophy by up to 62% and reduce neuroinflammation in mild Alzheimer's patients. Review of laromestrocel trial data, biomarker outcomes, and emerging treatment options.

Читать далее...

MSC Therapy for Systemic Sclerosis: iPSC-Derived Stem Cells, Clinical Trials, and the Vasculopathy-Fibrosis Mechanism

A comprehensive 2026 review of mesenchymal stem cell therapy for systemic sclerosis (scleroderma), covering iPSC-derived MSCs, refrigerated cell delivery, blood vessel organoid models, and the MANUS clinical trial for digital ulcers.

Читать далее...

Stem Cell Therapy for Low Back Pain: What the 2025–2026 Clinical Trials Actually Show

Three major clinical trials — including a 404-patient 3-year study — are finally giving us real data on whether MSC therapy works for chronic low back pain and degenerative disc disease. Here's what the evidence says, in plain language.

Читать далее...

MSC Therapy for Chronic Kidney Disease: What the 2025 Evidence Shows

A 2025 meta-analysis of 52 studies, real-world Taiwan data, and Mayo Clinic intraarterial delivery results — what nephrologists need to know about MSCs and CKD.

Читать далее...

MSC Therapy for Pulmonary Fibrosis: 2026 Preclinical and Clinical Evidence Review

A medical review of MSC-based and MSC-derived EV therapies for idiopathic pulmonary fibrosis, covering meta-analysis data, immune-cloaked cell engineering, nebulized exosome delivery, gut-lung axis mechanisms, and active clinical trials.

Читать далее...

MSC Therapy for Ischemic Stroke: What a 2026 Umbrella Review and Network Meta-Analysis of 1,006 Patients Reveal

The 2026 evidence base for mesenchymal stem cell therapy in ischemic stroke includes a 26-study umbrella review and an 18-RCT network meta-analysis of 1,006 patients. MSCs were the only cell type to significantly reduce mortality. This medical review synthesizes the latest clinical data, mechanisms, active trials, and translational barriers.

Читать далее...

Дышать легче: как терапия стволовыми клетками меняет лечение ХОБЛ в Таиланде

В нашей клинике в Бангкоке изучают, как терапия с использованием мезенхимальных стволовых клеток помогает пациентам с ХОБЛ легче дышать — уменьшая воспаление, активируя стволовые клетки легких и улучшая качество жизни.

Читать далее...

Сколько будет стоить терапия стволовыми клетками в 2026 году? Реалистичное руководство для пациентов.

Стоимость терапии стволовыми клетками варьируется от $2000 до $100000 в зависимости от места проведения. Вот что на самом деле влияет на стоимость, что входит в пакет услуг и как Таиланд соотносится с США, Австралией и Европой в 2026 году.

Читать далее...

MSC Therapy for Graft-versus-Host Disease: What 15 RCTs and a Biomarker-Guided Trial Tell Us

A 2026 meta-analysis of 15 RCTs shows MSCs cut acute GvHD incidence by 53% and chronic GvHD by 50%. A biomarker-guided trial identifies which transplant patients benefit most — and a cell-free exosome approach may be next.

Читать далее...
Вершина